Screening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound
DACEP
1 other identifier
interventional
400
1 country
5
Brief Summary
Abdominal aortic aneurysm (AAA) is a localized dilatation of a segment of the aorta artery in its abdominal portion. It affects 1.7% of men aged 65 years and older. In the high-risk population (male smokers aged 65-75 years), its prevalence is estimated to be between 2.8 and 9%. Mortality of ruptured AAAs is high (80% of deaths before hospitalization or perioperatively), whereas mortality of scheduled procedures for unruptured AAAs is less than 5%. AAA screening has been shown to significantly reduce the specific mortality rate in the medium and long term. The French National Authority for Health (HAS) recommends targeted screening for AAA by ultrasound at the radiologist. The target population is male smokers or former smokers aged 65 to 75 years, as well as all persons aged 50 to 75 years with a family history of AAA. Despite recommendations, the rate of access to targeted screening appears low. Ultrasound screening for AAA is a rapid, noninvasive, and reproducible test. It relies primarily on the measurement of the maximum diameter of the abdominal aorta in cross-section. It has been demonstrated that the learning of the ultrasound screening procedure for AAA is very fast and that the performance of non-radiologists trained in this procedure alone is similar to that of radiologists. In addition, new ultra-portable ultrasound devices, inexpensive and with validated performances have appeared on the market in the last few years, making it possible to equip general practitioners (GPs). We propose a simplified care pathway for AAA screening, by equipping GPs with an ultra-portable ultrasound scanner and by training them to perform the screening procedure, which will be performed in the office or at the patient's home, during a usual consultation of general medicine. Our hypothesis is that this new organization will allow better access to screening for the target population, at a lower cost, compared to the current screening method recommended by the HAS (referral of the patient to the radiologist).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2023
Longer than P75 for not_applicable
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2022
CompletedFirst Posted
Study publicly available on registry
November 15, 2022
CompletedStudy Start
First participant enrolled
October 2, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2027
December 17, 2025
December 1, 2025
3.9 years
November 8, 2022
December 9, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
AAA screening performed at 1 year
Percentage of included patients (eligible for AAA screening) who actually received AAA screening ultrasound within 1 year of the inclusion visit
1 year
Study Arms (2)
screening by a GP
EXPERIMENTALEach patient in this group will have a screening for AAA performed by a trained general practitioner
screening by a radiologist (conventional)
OTHEREach patient in this group will have AAA screening performed by a radiologist
Interventions
General practitioners in the control group will refer their patients to the radiologist for AAA screening.
The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..
Eligibility Criteria
You may qualify if:
- Male
- In the absence of a family history of AAA: Patient aged 65 to 75 years, chronic current or past smoker, active smoker (defined as having smoked at least one cigarette per day) or former smoker (defined as having quit smoking less than 20 years ago, regardless of the number of cigarettes smoked).
- If there is a family history of AAA: Patient between 50 and 75 years of age
- Express consent to participate in the study
- Affiliated or beneficiary of a social security plan
You may not qualify if:
- Patient with a legal protection measure
- Patient with previous AAA screening less than 5 years old
- Patient unable to understand the study / give informed consent (cognitive impairment, communication impairment)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
Cabinet IPSO Brotteaux
Lyon, 69006, France
Cabinet IPSO Saint Martin
Paris, 75003, France
Cabinet IPSO Nation
Paris, 75011, France
Cabinet IPSO Italie
Paris, 75013, France
Cabinet IPSO Ourcq
Paris, 75019, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hervé Picard, MD
Hôpital Fondation A. de Rothschild
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 8, 2022
First Posted
November 15, 2022
Study Start
October 2, 2023
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2027
Last Updated
December 17, 2025
Record last verified: 2025-12